SCHEMBL5542902

SCHEMBL5542902

CN(C[C@](C)(O)Cn1cc([N+](=O)[O-])nc1Cl)c1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.38
KMT2A Q03164 2/20 0.37
MAPT P10636 1/20 0.37
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
POLB P06746 1/20 0.35
ALDH1A1 P00352 1/20 0.35
SOS1 Q07889 1/20 0.35
LMNA P02545 2/20 0.34
MITF O75030 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542905 1.00 PKM (0.38) PKMKMT2AMAPTCRHBPCRHR2
SCHEMBL5536730 0.91 KMT2A (0.44) PKMKMT2AMAPTPOLBALDH1A1
SCHEMBL5536734 0.91 KMT2A (0.44) PKMKMT2AMAPTPOLBALDH1A1
SCHEMBL5539824 0.85 PKM (0.36) PKMKMT2APOLBALDH1A1SOS1
SCHEMBL5539822 0.85 PKM (0.36) PKMKMT2APOLBALDH1A1SOS1
SCHEMBL5536277 0.79 SOS1 (0.37) PKMKMT2AMAPTALDH1A1SOS1
SCHEMBL5536273 0.79 SOS1 (0.37) PKMKMT2AMAPTALDH1A1SOS1
SCHEMBL5535327 0.79 KMT2A (0.43) PKMKMT2AALDH1A1SOS1
SCHEMBL5536388 0.79 ALDH1A1 (0.43) PKMKMT2APOLBALDH1A1SOS1
SCHEMBL5537618 0.79 ALDH1A1 (0.43) PKMKMT2APOLBALDH1A1SOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PKM 4291/4885KMT2A 4267/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.